Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 17/20 | 0.59 |
| ▸ | MC5R | P33032 | 16/20 | 0.59 |
| ▸ | MC3R | P41968 | 13/20 | 0.59 |
| ▸ | MC1R | Q01726 | 13/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309435 | 1.00 | MC4R (0.59) | MC4RMC5RMC3RMC1RCYP3A4 | |
| SCHEMBL1308699 | 0.91 | MC4R (0.49) | MC4RMC5RMC3RMC1RCYP3A4 | |
| SCHEMBL1308702 | 0.91 | MC4R (0.49) | MC4RMC5RMC3RMC1RCYP3A4 | |
| SCHEMBL1308557 | 0.91 | MC4R (0.49) | MC4RMC5RMC3RMC1RKMT2A | |
| SCHEMBL1308553 | 0.91 | MC4R (0.49) | MC4RMC5RMC3RMC1RKMT2A | |
| SCHEMBL6200842 | 0.84 | MC4R (0.55) | MC4RMC5RMC3RMC1RCYP3A4 | |
| SCHEMBL7658037 | 0.83 | MC4R (0.53) | MC4RMC5RMC3RMC1RCYP3A4 | |
| SCHEMBL7658043 | 0.83 | MC4R (0.53) | MC4RMC5RMC3RMC1RCYP3A4 | |
| SCHEMBL6200844 | 0.83 | MC4R (0.58) | MC4RMC5RMC3RMC1RCYP3A4 | |
| SCHEMBL1309061 | 0.82 | MC4R (0.56) | MC4RMC5RMC3RMC1RCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877968-B2 | Melanocortin receptor modulators, process for preparing them and use there in human medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-11-04 | — | — | US | disclosed |
| EP-2352728-B1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2014-05-21 | — | — | EP | disclosed |
| US-20120301458-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20110275657-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-10 | — | — | US | disclosed |
| EP-2352728-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | Galderma Research & Development (FR) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010052255-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120301458-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | MC4R 486/4885MC5R 310/4885MC3R 327/4885 |
| US-20110275657-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS | MC1R, MC5R, MC3R | MC4R 4/4885MC5R 2/4885MC3R 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.